hrp0095rfc11.4 | Late Breaking | ESPE2022

Are GnRH agonists beneficial in final adult height after 8 years old? Data from a Portuguese National Digital Platform of idiopathic Central Precocious Puberty

Espada Filipa , Castro Carolina , Luisa Leite Ana , Galo Elisa , Antunes Ana , Castro Sofia , Robalo Brigida , Amaral Daniela , Ferreira Sofia , Limbert Catarina

Objective: Central precocious puberty (CPP) is a common condition in pediatric endocrinology practice. Gonadotropin-releasing hormone agonists (GnRHa) treatment is safe, but the real effect on final height and the ideal timing for treatment remains controversial. The purpose of the authors was to evaluate a nationwide representative group of CPP Portuguese girls treated with GnRHa, assess the effectiveness of treatment and the growth outcome before and after 8...

hrp0098p2-385 | Late Breaking | ESPE2024

Integrating Genetic Testing in the Evaluation of Boys with Central Precocious Puberty: A Portuguese Nationwide Study

Galo Elisa , Vidal Castro Sofia , Amaral Daniela , Espada Filipa , Brandão Carla , Luísa Leite Ana , Ferreira Sofia , Caetano Francisco , Cerqueira Rita , Limbert Catarina

Introduction: Precocious development of secondary sexual characteristics in both sexes indicates early reactivation of the hypothalamic-pituitary-gonadal axis, known as central precocious puberty (CPP). CPP should be considered in males under nine years old when testicular volume exceeds 4 milliliters. This condition is rare (1 male per 15 girls), and secondary causes must be promptly excluded due to the higher likelihood of intracranial pathology. Recent stud...